in silico methods in fragment-based drug design — a Protein Kinase B case study

webinar

Wed, 28 Jan 2015, 19:00 CET (Berlin)

Dr. Alastair Donald, BioSolveIT GmbH, St. Augustin, Germany

in silico methods in fragment-based drug design — a Protein Kinase B case study

Computational tools are invaluable in the process of identifying high-quality fragment hits. In this one hour BioSolveIT webinar you will learn how to fast-track your fragment hit discovery using our cutting edge in silico solutions using Protein Kinase B as an example.

By the end you will appreciate how our suite of SBDD tools can enrich your work life, enhance your productivity and assist in the identification of potent, selective and synthetically accessible lead-like molecules.

So, if you are interested in

  • enriching your screening collection with potent and selective fragments
  • intelligently selecting which commercially available analogs to purchase
  • deciding which analogs to prioritize for synthesis
  • saving time and money by focusing on the most promising ideas

watch the video live recording below.

Current news

Tool of the Month - infiniSee 7.1 'Arke'
May 27, 2026 09:44 CEST
Navigate Chemical Space with infiniSee 7.1 ‘Arke’ The ultimate platform for exploring ultra-large Chemical Spaces is taking a huge leap forward. Combining our Tool of the Month series with an exciting software release, we are happy to present infiniSee 7.1 ‘Arke’. Allowing you to search deeper and evaluate compounds more...
Read on
category
Software
infiniSee 7.1 'Arke' Is Now Available
May 26, 2026 16:49 CEST
We are delighted to introduce infiniSee 7.1 ‘Arke’, another helpful step forward in making the exploration of vast Chemical Spaces faster, clearer, and more intuitive. With this update, we focused on two central goals: helping users move through ultra-large Chemical Spaces more efficiently and making compound assessment more visual and...
Read on
VAST™ Space by XtalPi - Access now with our tools
May 21, 2026 10:42 CEST
The VAST™ Space brings an actionable, navigable universe of 4.66 billion accessible, drug-like products directly into your workflow. Created by XtalPi, this collection was built from 40+ validated reaction protocols and 58,000 in-stock building blocks. By pairing automated synthesis with proprietary feasibility models, it delivers a highly reliable and innovative...
Read on